Last reviewed 2026-04-23 · How we verify

Physician's choice of chemotherapy.

Physician's choice of chemotherapy. is a Small molecule drug developed by MacroGenics. It is currently in Phase 3 development for Control arm in phase 3 oncology trials (specific indication depends on trial protocol).

This is a placeholder term referring to standard chemotherapy regimens selected by the treating physician, rather than a specific drug entity.

This is a placeholder term referring to standard chemotherapy regimens selected by the treating physician, rather than a specific drug entity. Used for Control arm in phase 3 oncology trials (specific indication depends on trial protocol).

At a glance

Mechanism of action

Physician's choice of chemotherapy is a trial design approach in which the treating oncologist selects from approved chemotherapy agents (such as platinum-based, taxane, or other cytotoxic drugs) based on patient factors and disease characteristics. This is commonly used as a control arm in oncology trials to compare investigational agents against standard-of-care chemotherapy.

Approved indications

• Control arm in phase 3 oncology trials (specific indication depends on trial protocol)

Common side effects

• Myelosuppression
• Nausea and vomiting
• Alopecia
• Peripheral neuropathy
• Fatigue

Key clinical trials

• A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (PHASE3)
• A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
• Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer (PHASE3)
• A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) (PHASE3)
• Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial (PHASE3)
• Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial (PHASE2)
• Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) (PHASE3)
• Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Physician's choice of chemotherapy. CI brief — competitive landscape report
• Physician's choice of chemotherapy. updates RSS · CI watch RSS
• MacroGenics portfolio CI

Frequently asked questions about Physician's choice of chemotherapy.

Related

• Manufacturer: MacroGenics — full pipeline
• Therapeutic area: All drugs in Oncology
• Indication: Drugs for Control arm in phase 3 oncology trials (specific indication depends on trial protocol)
• Compare: Physician's choice of chemotherapy. vs similar drugs
• Pricing: Physician's choice of chemotherapy. cost, discount & access